Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine

Prostate

Volumn 62, Issue 3, 2005, Pages 217-223

  Roos, Anna Karin ^a   Pavlenko, Maxim ^a   Charo, Jehad ^b   Egevad, Lars ^c   Pisa, Pavel ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CTL; DNA vaccine; IFN ; Immunotherapy; Prostate specific antigen

Indexed keywords

CANCER VACCINE; CHROMIUM 51; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EMBRYO; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROVOCATION TEST; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 12344338245     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20135     Document Type: Article

References (32)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2001.
2. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9(2):83-93.
3. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-391.
4. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. Int J Cancer 1995;63(2):231-237.
5. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53(2):109-117.
6. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109(3):409-417.
7. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57(1):80-92.
8. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB, Shoemaker H. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998;17(24):3125-3135.
9. Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001;20(33):4497-4506.
10. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001;7(Suppl 3):882s-889s.
11. Horig H, Lee CS, Kaufman HL. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002;2(4):395-408.
12. Liu MA. DNA vaccines: A review. J Intern Med 2003;253(4):402-410.
13. Shedlock DJ, Weiner DB. DNA vaccination: Antigen presentation and the induction of immunity. J Leukoc Biol 2000;68(6):793-806.
14. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-1468.
15. Dubensky TW, Jr., Liu MA, Ulmer JB. Delivery systems for gene-based vaccines. Mol Med 2000;6(9):723-732.
16. Donnelly J, Berry K, Ulmer JB. Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 2003;33(5-6):457-467.
17. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001;19(17-19):2647-2656.
18. Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res 1995;55(11):2455-2462.
19. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000;74(1):41-44.
20. Jones T, Stern A, Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994;13(Suppl 2):S47-S53.
21. Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. J Virol 2000;74(7):3427-3429.
22. Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, Ciccarelli R, Agadjanyan MG, Weiner DB. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999;19(1):77-84.
23. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000;164(6):3102-3111.
24. Luo Y, O'Hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, James Primus F, Xiang R. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003;21(17-18):1938-1947.
25. Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol 1998;28(11):3530-3540.
26. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002;76(1):243-250.
27. Otten GR, Chen M, Doe B, zur Megede J, Barnett S, Ulmer J. Quantitative assessment of antigen-specific CD8+ T cells in the mouse: Application to vaccine research. Immunol Lett 2003;85(2):215-222.
28. Michel N, Ohlschlager P, Osen W, Freyschmidt EJ, Guthohrlein H, Kaufmann AM, Muller M, Gissmann L. T cell response to human papillomavirus 16 E7 in mice: Comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT, and tetramer staining. Intervirology 2002;45(4-6):290-299.
29. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-2368.
30. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003;15(2):131-137.
31. Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998;161(4):1875-1882.
32. Kwissa M, Kroger A, Hauser H, Reimann J, Schirmbeck R. Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. J Mol Med 2003;81(2):91-101.